Cargando…
Tetrabenazine in the treatment of Huntington’s disease
Tetrabenazine (TBZ), a catecholamine-depleting agent initially developed for the treatment of schizophrenia, when tested for other indications, has proven to be more useful for the treatment of a variety of hyperkinetic movement disorders. These disorders include neurological diseases characterized...
Autor principal: | Paleacu, Diana |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656291/ https://www.ncbi.nlm.nih.gov/pubmed/19381278 |
Ejemplares similares
-
Tetrabenazine is neuroprotective in Huntington's disease mice
por: Wang, Hongyu, et al.
Publicado: (2010) -
Management of Huntington’s disease: role of tetrabenazine
por: de Tommaso, Marina, et al.
Publicado: (2011) -
Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease
por: Ferrara, Joseph M., et al.
Publicado: (2012) -
Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease
por: Claassen, Daniel O., et al.
Publicado: (2017) -
Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?
por: Rodrigues, Filipe B., et al.
Publicado: (2017)